Rezafungin

From WikiProjectMed
Jump to navigation Jump to search
Rezafungin
Rezafungin.svg
Names
Trade namesRezzayo
Other namesBiafungin; CD101
Clinical data
Drug classEchinocandin[1]
Main usesInvasive candidiasis[1]
Side effectsLow potassium, fever, diarrhea, nausea, low magnesium, abdominal pain, infusion reaction, sun sensitivity, liver problems[1]
Legal
License data
Chemical and physical data
FormulaC63H85N8O17+
Molar mass1226.4 g/mol

Rezafungin, sold under the brand name Rezzayo, is an antifungal medication used to treat invasive candidiasis, including candidemia.[1] Specifically it is used in adults with few or no alternative treatment options.[1][2] It is given by slow injection into a vein.[1]

Common side effects include low potassium, fever, diarrhea, nausea, low magnesium, abdominal pain, and constipation.[1] Other side effects may include infusion reactions, sun sensitivity, and liver problems.[1] Safety in pregnancy is unclear.[1] It is in the echinocandin class of medication.[1][3]

Rezafungin was approved for medical use in the United States in 2023.[1] It is expected to become available in the United States in the summer of 2023 and to be expensive.[4] It received an orphan medication designation in Europe in 2021.[5]

Medical uses

Dosage

It is given at an initial dose of 400 mg, which is followed by 200 mg once per week for three more weeks.[1]

References

  1. 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 1.11 "DailyMed - REZZAYO- rezafungin injection, powder, lyophilized, for solution". dailymed.nlm.nih.gov. Archived from the original on 2 July 2023. Retrieved 21 June 2023.
  2. "Rezzayo approved by FDA amid rapid Candida auris spread". thepharmaletter.com. March 23, 2023. Archived from the original on July 1, 2023. Retrieved April 4, 2023.
  3. Zhao Y, Perlin DS (September 2020). "Review of the Novel Echinocandin Antifungal Rezafungin: Animal Studies and Clinical Data". Journal of Fungi. 6 (4): 192. doi:10.3390/jof6040192. PMC 7712954. PMID 32998224.
  4. "Rezafungin (Rezzayo)". IDStewardship. 23 March 2023. Archived from the original on 12 May 2023. Retrieved 21 June 2023.
  5. "EU/3/20/2385". European Medicines Agency. 18 May 2021. Archived from the original on 1 April 2023. Retrieved 22 June 2023.

External links

Identifiers: